AGREE REALTY CORP
AGREE REALTY CORP (ADC) Stock News
The latest ADC headlines and market coverage — 4 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation
Akari Therapeutics announced a strategic research collaboration with WhiteHawk Therapeutics to combine Akari's PH1 spliceosome-modulating payload with WhiteHawk's TOP1 inhibitor ADC platform for a novel dual-payload strategy. The company is advancing its lead candidate AKTX-101 toward Phase 1 clinical evaluation by mid-2027 and emphasizes that collaborations will play an increasingly important role in advancing next-generation ADC innovation.
- GlobeNewswire Inc.·
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
Novartis has agreed to acquire Myricx Bio for up to $1.5 billion ($1.1 billion upfront plus milestone payments) to advance next-generation antibody-drug conjugate (ADC) payloads using Myricx's novel N-myristoyltransferase inhibitor (NMTi) platform. The acquisition combines Novartis's oncology expertise with Myricx's differentiated ADC assets targeting solid tumors, addressing unmet needs in overcoming ADC resistance and improving tolerability.
- GlobeNewswire Inc.·
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026
Zymeworks presented Phase 1 data for ZW191, a folate receptor alpha-targeting antibody-drug conjugate, showing a confirmed objective response rate of 78.6% in FRα-positive platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients. The drug demonstrated a favorable tolerability profile with median progression-free survival of 7.6 months across ovarian and endometrial cancer cohorts. Patient recruitment in dose optimization cohorts has been completed, supporting continued clinical development.
- Benzinga·
RADCOM Delivers First Quarter 12% Y-o-Y Revenue Growth and Expanding Y-o-Y Operating Margins
<p xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">TEL AVIV, Israel</span>, <span xmlns="http://www.w3.org/1999/xhtml" class="legendSpanClass">May 19, 2026</span> /PRNewswire/ -- <b xmlns="http://www.w3.org/1999/xhtml">RADCOM Ltd. </b>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/RDCM" rel="nofollow">RDCM</a>), a leading provider of advanced, intelligent assurance solutions with integrated AI Operations (AIOps) capabilities, announced today its financial results for the first quarter ended March 31, 2026.</p> <p xmlns="http://www.w3.org/1999/xhtml">&#34;We delivered another quarter of sustained, profitable growth, with first-quarter revenue of $18.6 million, up 12% year-over-year,&#34; said Benny Eppstein, RADCOM&#39;s Chief Executive Officer. &#34;Our focused execution continues to translate top-line growth into expanding margins, reinforced by a multi-year renewal with a Tier-1 operator that expands its RADCOM ACE footprint to power more AI-driven, automated network operations.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml">&#34;Looking ahead, we&#39;re encouraged by customers&#39; reception of RADCOM Neura, our AI agent suite designed for integration into agentic AI ecosystems,&#34; Eppstein continued. &#34;We remain focused on disciplined execution, deepening installed-base relationships, winning new customers, and advancing our AI-native, event-driven assurance capabilities as networks move toward greater automation.&#34;</p> <p xmlns="http://www.w3.org/1999/xhtml">RADCOM is reaffirming its full-year 2026 revenue guidance of 8% to 12% year-